Affordable Access

deepdyve-link
Publisher Website

OX40/OX40 ligand interactions in T-cell regulation and asthma.

Authors
  • Kaur, Davinder1
  • Brightling, Christopher2
  • 1 Institute for Lung Health, Department of Infection, Inflammation, and Immunity, University of Leicester, Leicester, England.
  • 2 Institute for Lung Health, Department of Infection, Inflammation, and Immunity, University of Leicester, Leicester, England. Electronic address: [email protected]
Type
Published Article
Journal
CHEST Journal
Publisher
Elsevier
Publication Date
February 2012
Volume
141
Issue
2
Pages
494–499
Identifiers
DOI: 10.1378/chest.11-1730
PMID: 22315115
Source
Medline
License
Unknown

Abstract

The OX40 receptor is preferentially expressed by T cells, and its cognate ligand OX40L is primarily expressed by antigen-presenting cells such as dendritic cells following activation by thymic stromal lymphopoietin (TSLP). TSLP is released by the bronchial epithelium, airway smooth muscle, and some inflammatory cells in response to numerous insults such as allergens, viruses, and physical damage. OX40L is a costimulatory molecule that plays a sentinel role in the adaptive immune response by promoting T helper (Th) 2 polarization of naive T cells within the lymph node. These polarized T cells produce Th2 cytokines such as IL-4, IL-5, and IL-13, which have been implicated particularly in allergic eosinophilic asthma. Animal models have positioned both TSLP and OX40/OX40L as critical in the development of airway inflammation and hyperreactivity. In human disease, there is good evidence that TSLP is upregulated in asthma, but there are limited data to demonstrate overexpression of OX40 or OX40L in disease. Targeting the OX40/OX40L axis or TSLP presents a novel therapeutic strategy that has the potential of modifying the disease process and, therefore, impacting on its natural history. Whether this approach can demonstrate efficacy in established disease rather than at disease onset is unknown. Biologic therapies directed toward OX40/OX40L are in early phases of development, and results from these studies are eagerly awaited.

Report this publication

Statistics

Seen <100 times